The U.S. Drug Enforcement Administration’s NFLIS-Drug 2020 Mid-Year report is now available. DEA provides the following five highlights of their analyses. Additional information is available in the full report here.

• From January 1, 2020, through June 30, 2020, an estimated 355,104 distinct drug cases were
  submitted to State and local laboratories in the United States and analyzed by September 30, 2020. From these cases, an estimated 612,426 drug reports were identified. The total number
  of drugs reported to the National Forensic Laboratory Information System (NFLIS) for the
  NFLIS-Drug 2020 Midyear Report is substantially lower than the number reported in the
  previous year. Please see the Notice of Decrease in Drug Reports on page ii.
• Methamphetamine was the most frequently identified drug (177,794 reports), followed by cannabis/THC (98,243 reports), cocaine (79,467 reports), fentanyl (49,284 reports), and heroin (46,476 reports). These five most frequently identified drugs accounted for approximately 74% of all drug reports.
• In the first half of 2020, methamphetamine accounted for 92% of identified phenethylamine reports, fentanyl accounted for 56% of identified narcotic analgesic reports, and alprazolam accounted for 42% of identified tranquilizer and depressant reports.
• Among identified synthetic cannabinoids, 5F-MDMB-PICA accounted for 30% of reports, while fluoro-MDMB-PICA, MDMB-4en-PINACA, and 4F-MDMB-BUTINACA accounted for another 36% of reports.
• Methamphetamine was the most frequently identified drug in the West (42%), Midwest (29%), and South (32%), while cocaine was the most frequently identified drug in the Northeast (22%).